<DOC>
	<DOCNO>NCT01045317</DOCNO>
	<brief_summary>To investigate pharmacokinetics PF-04776548 follow administration micro-dose PF-04776548 via intravenous oral route .</brief_summary>
	<brief_title>A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low ( Micro ) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Healthy male subject age 18 65 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 21 drinks/week ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>micro-dose</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>open label</keyword>
	<keyword>PF-04776548</keyword>
</DOC>